NR2F1 and lung carcinoma: Furthermore, NR2F1-driven dormancy is supported by downstream effectors, including the SRY-Box Transcription Factor 9 (SOX9), retinoic acid receptor β (RARβ), and cyclin-dependent kinase inhibitors, which synergistically enforce cell cycle arrest and promote the long-term quiescence of dormant lung cancer cells [47].